RxDoctor Payments Data

Emily Merritt, PA

Physician Assistant · Lexington, KYNPI 1801264387

Payments from drug & device makers

$823in general payments, 2019–2025

Across 31 payments — averaging $26.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$196
  • Johnson & Johnson$135
  • Boehringer Ingelheim$133
  • AstraZeneca$107
  • Novartis$78
  • AbbVie$47
  • plus $127 from 7 others

What the payments were for

  • Food & beverage$80798%
  • Entertainment$162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$823 in reported general payments places this provider in the 65th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$31,204
Medicare patients
303
Services billed
396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban214$197,859
XareltoRivaroxaban48$50,310
EntrestoSacubitril/Valsartan13$14,202
Dofetilide20$3,854
Amiodarone Hcl93$2,995
Metoprolol Succinate122$1,523
Mexiletine Hcl15$1,274
SotalolSotalol Hcl80$1,162
Flecainide Acetate54$820
Metoprolol Tartrate43$372
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$343
Atorvastatin Calcium22$178
Carvedilol23$177
Amlodipine Besylate39$131
Losartan Potassium22$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$135$50,31048 claims
NovartisEntresto$78$14,20213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →